Vice President, Lifecycle Leader, Daraxonrasib – Lung Cancer

Job description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a strategic, enterprise-minded Lifecycle Leader to lead the global lifecycle strategy for the daraxonrasib Lung Cancer program. This role is accountable for shaping and executing an integrated end-to-end molecule strategy — from pivotal development through commercialization and post-launch expansion — to maximize long-term patient and enterprise value. The Lifecycle Leader serves as the c...